The Safety and Efficacy of KAI-1678- An Inhibitor of Epsilon Protein Kinase C (εPKC)-Versus Lidocaine and Placebo for the Treatment of Postherpetic Neuralgia: A Crossover Study Design

Pain Medicine (United States)

Volumn 14, Issue 4, 2013, Pages 533-540

  Cousins, Michael J ^a   Pickthorn, Karen ^b   Huang, Saling ^b   Critchley, Linda ^a   Bell, Gregory ^b,c  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b KAI Pharmaceuticals   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Analgesic; Epsilon Protein Kinase C Inhibitor; KAI 1678; Postherpetic Neuralgia

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; KAI 1678; LIDOCAINE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROTEIN KINASE C INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANALGESIC ACTIVITY; ARTICLE; BRAIN ISCHEMIA; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPIGASTRIC PAIN; FEMALE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HERPES ZOSTER; HUMAN; INFUSION SITE PAIN; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; NEUROPATHIC PAIN; NUMERICAL RATING SCALE; PAIN ASSESSMENT; POSTHERPETIC NEURALGIA; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RISK REDUCTION; SCORING SYSTEM; SIDE EFFECT; SLURRED SPEECH; SOMNOLENCE; TREATMENT OUTCOME; UNSTEADINESS; VOMITING;

AGED; AGED, 80 AND OVER; ANESTHETICS, LOCAL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LIDOCAINE; MALE; MIDDLE AGED; NEURALGIA, POSTHERPETIC; PAIN MEASUREMENT; PEPTIDES; PROTEIN KINASE C-EPSILON; PROTEIN KINASE INHIBITORS; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 84876183998     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/pme.12058     Document Type: Article

References (22)

1. Gnann JW Jr, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med 2002;347:340-346.
2. Cunningham AL, Dworkin RH. The management of post-herpetic neuralgia. BMJ 2000;321:778-779.
3. Cunningham AL, Breuer J, Dwyer DE, etal. The prevention and management of herpes zoster. Med J Aust 2008;188:171-176.
4. Araujo LQ, Macintyre CR, Vujacich C. Epidemiology and burden of herpes zoster and post-herpetic neuralgia in Australia, Asia and South America. Herpes 2007;14(suppl 2):40-44.
5. Dray A, Bettaney J, Forster P, etal. Bradykinin-induced stimulation of afferent fibres is mediated through protein kinase C. Neurosci Lett 1988;91:301-307.
6. Rang HP, Ritchie JM. Depolarization of nonmyelinated fibers of the rat vagus nerve produced by activation of protein kinase C. J Neurosci 1988;8:2606-2617.
7. Schepelmann K, Messlinger K, Schmidt RF. The effects of phorbol ester on slowly conducting afferents of the cat's knee joint. Exp Brain Res 1993;92:391-398.
8. Cesare P, McNaughton P. A novel heat-activated current in nociceptive neurons and its sensitization by bradykinin. Proc Natl Acad Sci U S A 1996;93:15435-15439.
9. Burgess GM, Mullaney I, McNeill M, etal. Second messengers involved in the mechanism of action of bradykinin in sensory neurons in culture. J Neurosci 1989;9:3314-3325.
10. McGuirk SM, Dolphin AC. G-protein mediation in nociceptive signal transduction: An investigation into the excitatory action of bradykinin in a subpopulation of cultured rat sensory neurons. Neuroscience 1992;49:117-128.
11. Aley KO, Messing RO, Mochly-Rosen D, etal. Chronic hypersensitivity for inflammatory nociceptor sensitization mediated by the epsilon isozyme of protein kinase C. J Neurosci 2000;20:4680-4685.
12. Minami T, Okuda-Ashitaka E, Mori H, etal. Characterization of nociceptin/orphanin FQ-induced pain responses in conscious mice: Neonatal capsaicin treatment and N-methyl-D-aspartate receptor GluRepsilon subunit knockout mice. Neuroscience 2000;97:133-142.
13. Csukai M, Mochly-Rosen D. Pharmacologic modulation of protein kinase C isozymes: The role of RACKs and subcellular localisation. Pharmacol Res 1999;39:253-259.
14. Mochly-Rosen D. Localization of protein kinases by anchoring proteins: A theme in signal transduction. Science 1995;268:247-251.
15. Lesser H, Sharma U, LaMoreaux L, etal. Pregabalin relieves symptoms of painful diabetic neuropathy: A randomized controlled trial. Neurology 2004;63:2104-2110.
16. Galer BS, Jensen MP, Ma T, etal. The lidocaine patch 5% effectively treats all neuropathic pain qualities: Results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the neuropathic pain scale. Clin J Pain 2002;18:297-301.
17. Jensen MP, Dworkin RH, Gammaitoni AR, etal. Assessment of pain quality in chronic neuropathic and nociceptive pain clinical trials with the Neuropathic Pain Scale. J Pain 2005;6:98-106.
18. Tremont-Lukats IW, Challapalli V, McNicol ED, etal. Systemic administration of local anesthetics to relieve neuropathic pain: A systematic review and meta-analysis. Anesth Analg 2005;101:1738-1749.
19. Carroll I, Gaeta R, Mackey S. Multivariate analysis of chronic pain patients undergoing lidocaine infusions: Increasing pain severity and advancing age predict likelihood of clinically meaningful analgesia. Clin J Pain 2007;23:702-706.
20. Thomson PD, Melmon KL, Richardson JA, etal. Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans. Ann Intern Med 1973;78:499-508.
21. Attal N, Rouaud J, Brasseur L, etal. Systemic lidocaine in pain due to peripheral nerve injury and predictors of response. Neurology 2004;62:218-225.
22. Rowbotham MC, Reisner-Keller LA, Fields HL. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology 1991;41:1024-1028.